Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Hikma Pharmaceuticals PLC (OTCMKTS:HKMPFGet Rating) have received an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $2,100.00.

Several research firms have recently issued reports on HKMPF. Morgan Stanley reduced their price objective on shares of Hikma Pharmaceuticals from GBX 2,300 ($28.17) to GBX 2,100 ($25.72) in a research report on Friday, May 6th. JPMorgan Chase & Co. cut shares of Hikma Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Wednesday, May 25th.

HKMPF opened at $18.19 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.06 and a quick ratio of 1.38. The company’s 50 day moving average is $22.48 and its 200 day moving average is $25.64. Hikma Pharmaceuticals has a 12-month low of $17.78 and a 12-month high of $37.70.

About Hikma Pharmaceuticals (Get Rating)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.

Recommended Stories

Analyst Recommendations for Hikma Pharmaceuticals (OTCMKTS:HKMPF)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.